Armata Pharmctcl Stock Price, News & Analysis

Armata Pharmaceuticals (ARMP) reported its second-quarter 2021 results, noting the retirement of CEO Todd R. Patrick and the appointment of Brian Varnum as his successor. The company received a $750,000 milestone payment from the Cystic Fibrosis Foundation to support its Phase 1b/2a clinical trial for AP-PA02 targeting chronic Pseudomonas aeruginosa infections. Grant revenue was $1.2 million, a significant increase from $31,000 in Q2 2020. However, R&D expenses surged to $5.2 million, contributing to an operating loss of $6.2 million. Armata has $17.5 million in cash as of June 30, 2021.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced on August 2, 2021, that CEO Todd R. Patrick is retiring from day-to-day management, transitioning to the Board of Directors as a special advisor. President Brian Varnum, Ph.D., has been appointed CEO. Patrick highlighted the company's significant progress, including the merger with AmpliPhi Biosciences and clinical trials for AP-PA02. The Board expressed gratitude for Patrick's leadership and confidence in Varnum's drug development experience as the company advances phage-based therapeutics targeting antibiotic-resistant infections.

Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology firm focused on bacteriophage therapeutics for antibiotic-resistant infections, will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 4:00 PM ET. The event will feature one-on-one investor meetings and further details about Armata's innovative pipeline targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Interested parties can access the presentation through a provided webcast link.

Armata Pharmaceuticals, Inc. (ARMP) reported first quarter 2021 results, highlighting progress in clinical trials and financial developments. The company is advancing its SWARM-P.a. Phase 1b/2a trial for treating cystic fibrosis and preparing for a Phase 1b/2 trial for Staphylococcus aureus bacteremia. Armata raised $20 million in gross proceeds from Innoviva, enhancing its financial position, which now includes $22.5 million in cash. The company recognized $1.1 million in grant revenue and expects to achieve several milestones in 2021 and 2022.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced its Q4 and full-year 2020 results, signaling progress in its clinical programs. The FDA cleared the IND application for its lead candidate AP-PA02, aimed at treating Pseudomonas aeruginosa infections. The company appointed Robin C. Kramer to its Board and Mina Pastagia as VP of Clinical Development. Financially, Armata reported Q4 revenues of $0.5 million and a loss from operations of $6.5 million. After raising $20 million from Innoviva, the company has approximately $9.7 million in cash, sufficient to fund operations into Q1 2022.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has successfully closed the second and final tranche of a $20 million private placement with Innoviva, Inc. (NASDAQ: INVA). This transaction raised approximately $13.9 million through the issuance of 4,285,935 common shares and warrants at $3.25 each, following a notable 99% shareholder approval. The first tranche, completed on January 26, 2021, raised $6.1 million. Following both closings, Armata now has 24,940,442 shares outstanding and warrants for 16,649,465 additional shares.

Armata Pharmaceuticals (NYSE American: ARMP) announces participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. Management will present on March 17 at 3:10pm ET. The company focuses on bacteriophage therapeutics targeting antibiotic-resistant bacterial infections, with a diverse pipeline including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. Armata collaborates with Merck to develop synthetic phage candidates for an undisclosed infectious disease.

Armata Pharmaceuticals (NYSE American: ARMP) announced a securities purchase agreement with Innoviva (Nasdaq: INVA), securing approximately $20 million in gross proceeds. The funds will support Armata's bacteriophage development programs, including the FDA-cleared SWARM-P.a. study for AP-PA02 targeting Pseudomonas aeruginosa infections. The agreement includes the purchase of 6.2 million shares at $3.25 each and warrants, scheduled in two tranches. Armata aims to achieve significant clinical milestones in 2021 and 2022, advancing its pipeline for combatting antibiotic-resistant infections.

Armata Pharmaceuticals announced the election of Robin C. Kramer to its Board of Directors on December 8, 2020. Currently serving as the VP and Chief Accounting Officer at Biogen, Kramer's extensive financial leadership experience is expected to bolster Armata's strategic direction. Directors H. Stewart Parker and Jeremy Curnock Cook did not seek re-election. CEO Todd R. Patrick expressed confidence in the enhanced board leadership during a critical phase of the company’s clinical development initiatives, focusing on solutions for antibiotic-resistant infections.